Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;177(4):1647-56.
doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer

Francisco J Esteva  1 , Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S Lanchbury, Aysegul A Sahin, Gabriel N Hortobagyi, Dihua Yu
Affiliations

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer

Francisco J Esteva et al. Am J Pathol. 2010 Oct.

Abstract

Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream signaling of phosphoinositide 3-kinase (PI3K), we investigated the role of PTEN and other components of the PI3K pathway in trastuzumab resistance. We analyzed the status of PTEN, p-AKT-Ser473, and p-p70S6K-Thr389 using immunohistochemistry. PIK3CA mutation status was analyzed by direct sequencing. Primary tumor tissue was available from 137 patients with HER2-overexpressing metastatic breast cancer who had received trastuzumab-based chemotherapy. We observed that each of the four biomarkers alone did not significantly correlate with trastuzumab response, whereas PTEN loss alone significantly correlated with shorter survival times (P = 0.023). PI3K pathway activation, defined as PTEN loss and/or PIK3CA mutation, was associated with a poor response to trastuzumab (P = 0.047) and a shorter survival time (P = 0.015). PTEN loss was significantly associated with a poor response to trastuzumab (P = 0.028) and shorter survival time (P = 0.008) in patients who had received first-line trastuzumab and in patients with estrogen receptor- (P = 0.029) and progesterone receptor-negative tumors (P = 0.033). p-AKT-Ser473 and p-p70S6K-Thr389 each had a limited correlation with trastuzumab response. When these markers were combined with PTEN loss, an increased correlation with patient outcome was observed. In conclusion, PI3K pathway activation plays a pivotal role in trastuzumab resistance. Our findings may facilitate the evaluation of tumor response to trastuzumab-based and _targeted therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Activation of the PI3K pathway was more significantly associated with trastuzumab resistance than PTEN status alone. A: Heterogeneous expression of the PTEN protein in invasive ductal carcinoma lesions examined by IHC in HER2-positive MBC tumors. B: Representative PTEN IHC staining (IRS = 0, 3, 12). Arrows point to fibroblasts and endothelial cells that showed high expression of PTEN, which served as an internal positive control. C: Poor response (P = 0.081) and significantly shorter OS (P = 0.023) after trastuzumab-based therapy in patients with PTEN loss alone (PTEN loss defined as IRS ≤3). D: Significantly poorer response (P = 0.047) and shorter OS (P = 0.015) after trastuzumab-based therapy in patients with PI3K pathway activation (defined as PTEN loss and/or PIK3CA mutation). Scale bar = 50 μm.
Figure 2
Figure 2
Combing either p-AKT+ or p-p70S6K+ with PTEN loss correlated with trastuzumab resistance. A: Representative IHC staining patterns of p-AKT and p-p70S6K in HER2-positive MBC tumors. B: Combining p-AKT+ and PTEN loss was a more powerful marker of trastuzumab resistance than PTEN loss alone. Patients with PTEN-loss/p-AKT+ tumors showed worse responses and significantly shorter survival times (P = 0.016) after trastuzumab-based therapy. C: Combining p-p70S6K+ and PTEN loss was a more powerful marker of trastuzumab resistance than PTEN loss alone. Patients with PTEN-loss/p-p70S6K+ tumors showed worse responses and significantly shorter OS (P = 0.008) after trastuzumab-based therapy. Scale bar = 50 μm.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182. - PubMed
    1. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst. 1998;90:1262–1269. - PubMed
    1. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21:177–184. - PubMed
    1. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res. 2003;9:511S–515S. - PubMed
    1. Emens LA. Trastuzumab: _targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther. 2005;12:243–253. - PubMed

Publication types

MeSH terms

  NODES
Association 4
INTERN 1
twitter 2